Answers are grounded in this paper and cite their sources.
Background HER2-targeted antibody–drug conjugates were recently approved in China for treatment of advanced or metastatic urothelial carcinoma (UC). We summarise emerging evidence supporting use of HER2-targeted regimens in patients with localized disease. Methods We searched MEDLINE, Embase, Web of Science, CENTRAL through March 29, 2026, and SinoMed, Wanfang and CNKI through October 14, 2025 to identify studies evaluating HER2-targeted therapies, in patients with localized UC. Random-effects meta-analyses pooled response rates, including pathological complete response (pCR). Clinical complete response (cCR) was stratified by response definition. Heterogeneity was assessed using Cochrane's Q test. Risk-of-bias (RoB) was assessed using ROBINS-I tool. The study was registered prospectively (CRD420250650326). Results Thirty-three studies comprising 970 patients were included (17 prospective); 30 tested disitamab vedotin (DV). In 13 studies testing DV-containing regimens as neoadjuvant therapy, the pooled pCR rate was 48% (95% CI 39–58%, N = 398; 54% among surgery-evaluable patients). Evidence was insufficient to establish an association between HER2 expression and pCR (risk ratio [RR] 0.82, 95% CI 0.52–1.29; p = 0.38; N = 72). In bladder-sparing studies, cCR was 65% (95% CI 44–82%) with definitions requiring complete absence of residual tumor and 54% (95% CI 41–67%) with definitions permitting residual Ta/Tis disease. Among included trials using DV, rate of grade ≥3 adverse events did not exceed 35% and was lower than that reported in studies evaluating other HER2-targeted agents. Major RoB concerns regarded outcome measurement as none of included trials was blinded. Conclusions DV-containing regimens show promising activity as neoadjuvant therapy in patients with bladder cancer. Current evidence is insufficient to establish an association between HER2 expression and response. Emerging data indicate possible role in bladder-sparing setting with low rates of toxicity and no G5 safety signals, although heterogeneous cCR definitions limit interpretation.
No takes yet. Share an insight, caveat, or question.
Suleja et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: